• Je něco špatně v tomto záznamu ?

Drug information by public health and regulatory institutions: Results of an 8-country survey in Europe

G. Formoso, M. Font-Pous, WD. Ludwig, D. Phizackerley, D. Bijl, J. Erviti, B. Pospíšilová, JL. Montastruc,

. 2017 ; 121 (3) : 257-264. [pub] 20161229

Jazyk angličtina Země Irsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18016812

PURPOSE: To evaluate the framework of drug information produced by public health and regulatory institutions in Europe. MATERIALS AND METHODS: We carried out a short survey asking editors of ISDB bulletins of the European region to indicate the main sources of drug information provided by public health and regulatory authorities in their countries, the specific kind of information produced and their opinions about strengths and weaknesses of such information. The availability of evaluations about the added therapeutic value of drugs and of tools facilitating the implementation of such information were particularly addressed and checked on the websites of those institutions. RESULTS: Answers pertaining to eight countries were available. Regulatory information and safety alerts are generally available, but just UK and Germany stand out by showing quite an advanced framework of evidence-based, comparative drug information for health professionals, decision-makers and for the general public. National plans to implement evidence-based drug information seem lacking. CONCLUSION: More efforts are warranted to develop sharp formats to make evidence-based drug information easier to access, understand and put in context, showing the place in therapy of medicines and their added therapeutic value. Harmonization of different sources, also at European level, would be important to favor their access and limit dispersion. Appropriate tools and specific plans are then necessary to favor implementation of information materials.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016812
003      
CZ-PrNML
005      
20180521103724.0
007      
ta
008      
180515s2017 ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.healthpol.2016.12.007 $2 doi
035    __
$a (PubMed)28073580
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Formoso, Giulio $u Health and Welfare Directorate, Emilia-Romagna, Bologna, Italy. Electronic address: giulio.formoso@regione.emilia-romagna.it.
245    10
$a Drug information by public health and regulatory institutions: Results of an 8-country survey in Europe / $c G. Formoso, M. Font-Pous, WD. Ludwig, D. Phizackerley, D. Bijl, J. Erviti, B. Pospíšilová, JL. Montastruc,
520    9_
$a PURPOSE: To evaluate the framework of drug information produced by public health and regulatory institutions in Europe. MATERIALS AND METHODS: We carried out a short survey asking editors of ISDB bulletins of the European region to indicate the main sources of drug information provided by public health and regulatory authorities in their countries, the specific kind of information produced and their opinions about strengths and weaknesses of such information. The availability of evaluations about the added therapeutic value of drugs and of tools facilitating the implementation of such information were particularly addressed and checked on the websites of those institutions. RESULTS: Answers pertaining to eight countries were available. Regulatory information and safety alerts are generally available, but just UK and Germany stand out by showing quite an advanced framework of evidence-based, comparative drug information for health professionals, decision-makers and for the general public. National plans to implement evidence-based drug information seem lacking. CONCLUSION: More efforts are warranted to develop sharp formats to make evidence-based drug information easier to access, understand and put in context, showing the place in therapy of medicines and their added therapeutic value. Harmonization of different sources, also at European level, would be important to favor their access and limit dispersion. Appropriate tools and specific plans are then necessary to favor implementation of information materials.
650    _2
$a systémy pro sběr zpráv o nežádoucích účincích léků $x normy $7 D016907
650    12
$a spotřebitelská bezpečnost produktů $x normy $7 D003257
650    _2
$a sběr dat $7 D003625
650    12
$a informační služby o lécích $7 D004346
650    _2
$a Evropa $7 D005060
650    _2
$a vládní regulace $7 D033161
650    _2
$a lidé $7 D006801
650    _2
$a léky na předpis $x normy $7 D055553
650    _2
$a postmarketingový dozor $x metody $x normy $7 D011358
650    _2
$a veřejné zdravotnictví $7 D011634
650    _2
$a průzkumy a dotazníky $7 D011795
655    _2
$a časopisecké články $7 D016428
700    1_
$a Font-Pous, Maria $u Pharmaceutical department, ULSS 20 Verona, Italy.
700    1_
$a Ludwig, Wolf-Dieter $u Head of hematology, oncology and cancer immunology, HELIOS Klinikum Berlin-Buch, Germany.
700    1_
$a Phizackerley, David $u Drug and Therapeutics Bulletin (DTB), London, UK.
700    1_
$a Bijl, Dick $u Geneesmiddelenbulletin, Utrecht, The Netherlands.
700    1_
$a Erviti, Juan $u Servicio Navarro de Salud, Sección de Información y Asesoría del Medicamento, Pamplona, Spain.
700    1_
$a Pospíšilová, Blanka $u State Institute for Drug Control, Praha, Czechia.
700    1_
$a Montastruc, Jean Louis $u Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Faculté de Médecine, CHU de Toulouse, France.
773    0_
$w MED00001995 $t Health policy (Amsterdam, Netherlands) $x 1872-6054 $g Roč. 121, č. 3 (2017), s. 257-264
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28073580 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180521103906 $b ABA008
999    __
$a ok $b bmc $g 1300436 $s 1013652
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 121 $c 3 $d 257-264 $e 20161229 $i 1872-6054 $m Health policy $n Health Policy $x MED00001995
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Možnosti archivace